We are live on
!
Find out more
ED
Exane Derivatives Portfolio holdings
AUM
$174M
1-Year Est. Return
7.84%
This Fund
S&P 500
This Quarter
Est. Return
+6.44%
1 Year Est. Return
-7.84%
3 Year Est. Return
+42.72%
5 Year Est. Return
+56.28%
10 Year Est. Return
–
AUM
$350M
AUM Growth
+$9.81M
(+2.9%)
Cap. Flow
-$17.4M
Cap. Flow
% of AUM
-4.98%
Top 10 Holdings %
Top 10 Hldgs %
22.15%
Holding
984
New
159
Increased
201
Reduced
274
Closed
107
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$7.69M |
| 2 |
RSX
VanEck Russia ETF
RSX
|
+$6.34M |
| 3 |
abrdn Physical Gold Shares ETF
SGOL
|
+$5.37M |
| 4 |
iShares S&P 500 Value ETF
IVE
|
+$4.77M |
| 5 |
iShares MSCI Saudi Arabia ETF
KSA
|
+$4.43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$6.86M |
| 2 |
Stellantis
STLA
|
+$5.95M |
| 3 |
iShares MSCI China ETF
MCHI
|
+$5.61M |
| 4 |
iShares MSCI South Africa ETF
EZA
|
+$3.63M |
| 5 |
VanEck Oil Services ETF
OIH
|
+$3.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 11.27% |
| 2 | Technology | 10.8% |
| 3 | Consumer Discretionary | 10.51% |
| 4 | Financials | 9.65% |
| 5 | Materials | 7.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
CRISPR Therapeutics
CRSP
$4.6B
| $80.8K | 0.02% |
+663
| New | +$100K |
|
452
Eastman Chemical
EMN
$7.74B
| $80.5K | 0.02% |
731
+700
| +2,258% | +$76K |
|
|
AVDL
453
DELISTED
Avadel Pharmaceuticals
AVDL
| $80.5K | 0.02% |
8,900
| – | – |
|
454
State Street
STT
$50.7B
| $79.9K | 0.02% |
+951
| New | +$73.7K |
|
455
UGI
UGI
$7.91B
| $79.7K | 0.02% |
1,944
+1,927
| +11,335% | +$74.5K |
|
|
PS
456
DELISTED
Pluralsight, Inc. Class A Common Stock
PS
| $78.8K | 0.02% |
3,526
-21,062
| -86% | -$452K |
|
457
Eagle Materials
EXP
$6.69B
| $78.6K | 0.02% |
585
+94
| +19% | +$11.4K |
|
458
Dycom Industries
DY
$12.7B
| $78.4K | 0.02% |
844
+117
| +16% | +$10.1K |
|
459
Incyte
INCY
$23.7B
| $77.1K | 0.02% |
949
-628
| -40% | -$53.6K |
|
460
Chemed
CHE
$6.76B
| $76.3K | 0.02% |
166
-8
| -5% | -$3.92K |
|
461
Intuit
INTU
$83.1B
| $75.5K | 0.02% |
197
| – | – |
|
462
PTC Therapeutics
PTCT
$6.29B
| $74.9K | 0.02% |
1,582
| – | – |
|
|
CMA
463
DELISTED
Comerica
CMA
| $74.8K | 0.02% |
+1,042
| New | +$68.2K |
|
464
Xcel Energy
XEL
$50.4B
| $74.7K | 0.02% |
1,123
-1,591
| -59% | -$101K |
|
|
SCHW
465
Charles Schwab
SCHW
$181B
| $74.4K | 0.02% |
+1,141
| New | +$69.2K |
|
466
Fox Class B
FOX
$21.3B
| $74.1K | 0.02% |
2,122
-564
| -21% | -$18.9K |
|
467
Columbus McKinnon
CMCO
$472M
| $73.9K | 0.02% |
1,400
+223
| +19% | +$10.6K |
|
468
Phathom Pharmaceuticals
PHAT
$953M
| $73.8K | 0.02% |
1,966
-661
| -25% | -$27.7K |
|
469
Tradeweb Markets
TW
$21.7B
| $73.5K | 0.02% |
+993
| New | +$68.2K |
|
|
GOEV
470
DELISTED
Canoo Inc. Class A Common Stock
GOEV
| $73K | 0.02% |
+18
| New | +$123K |
|
471
Ameresco
AMRC
$1.12B
| $72.8K | 0.02% |
1,498
+194
| +15% | +$10.7K |
|
472
The Bancorp
TBBK
$2.81B
| $71.8K | 0.02% |
+3,466
| New | +$67.4K |
|
473
Kinder Morgan
KMI
$70.6B
| $71.5K | 0.02% |
+4,297
| New | +$65.6K |
|
474
Northrop Grumman
NOC
$77.8B
| $71.5K | 0.02% |
221
| – | – |
|
475
Nurix Therapeutics
NRIX
$2.43B
| $71.5K | 0.02% |
+2,300
| New | +$87K |
|
Similar funds
PC
TWMP
LPWM
ACM
HWIS
LWM
EW
GDWAM
Exane Derivatives's Q1 2021 Portfolio in Review
As of Q1 2021, Exane Derivatives held 984 positions worth $350M, up 2.9% from $340M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Exane Derivatives withdrew a net $17.4M in Q1 2021, closing 107 positions and reducing 274 holdings. Its most notable exit was Amazon, an estimated $6.86M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 11% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Exane Derivatives opened a new position in Linde worth $11.3M.
- Exane Derivatives's largest Q1 2021 buy was Linde: 29,643 shares worth $11.3M.
- Exane Derivatives added most to VanEck Russia ETF in Q1 2021, an estimated $6.34M increase.
- Exane Derivatives's biggest Q1 2021 reduction was Stellantis, cutting an estimated $5.95M.
- Exane Derivatives fully exited Amazon in Q1 2021, selling an estimated $6.86M.
- Exane Derivatives's ten largest holdings make up 22% of its $350M portfolio in Q1 2021.
- Exane Derivatives opened 159 new positions and closed 107 in Q1 2021.
- Exane Derivatives's portfolio value rose 2.9% quarter-over-quarter to $350M.
Based on Exane Derivatives's 13F filing for Q1 2021, filed 30 Apr 2021.